



Supplementary figure S1: Gender was prognostic for neuroblastoma patients. OS and EFS of 130 patients were estimated by Kaplan-Meier analysis within a 5-year period. (A) OS (log-rank test, P>0.05) and (B) EFS (log-rank test, P<0.05) of patient's dependent on gender.



Supplementary figure S2: (A) OS and (B) EFS of 130 patients in 5 years were calculated based on Age-groups by Kaplan-Meier method.

Pediatr Dimensions, 2019 doi: 10.15761/PD.1000195 Volume 4: 1-2



Supplementary figure S3: (A) OS and (B) EFS of 130 patients in 5 years were calculated based on the origin of a tumour by Kaplan-Meier method.

Supplementary table S1. Median for survival time.

	Median Survival Time (months)			
	OS time	<i>p</i> -value	EFS time	<i>p</i> -value
·		Gender		
Male	26.00 ± 2.697		29.00 ± 3.58	0.046
Female	26.00 ± 1.31		*	
		INSS stage		
Stage I, II and IVs	*	0.000	*	0.000
Stage III and IV	24.00 ± 1.772	0.000	27.00 ± 1.322	
		MYCN		
No	29.00 ± 1.82	0.000	*	0.000
Yes	18.00 ± 1.20		19.00 ± 2.96	

^{*} survival exceeds 50% at the longest time point, then median survival cannot be computed

 $NB = neuroblastoma; INSS = International \ Neuroblastoma \ Staging \ System; OS = Overall \ Survival; EFS = Event-free \ survival; \\ P-value \ less \ than \ 0.05 \ considered \ significant.$

Supplementary table S2. Interaction of MYCN-status with clinical factors in the effect on outcome of patients with NB.

Variables	Interaction HR and 95%CI	Interaction p-value
	Overall survival	•
MYCN-amplification Gender (male)	2.140 (1.115 – 4.108)	0.022
MYCN-amplification Age (>18 months)	3.573 (1.973 - 6.469)	0.000
	Event-free survival	
MYCN-amplification Gender (male)	2.199 (0.935 - 5.169)	0.071
MYCN-amplification Age (>18 months)	4.594 (1.635 – 12.912)	0.004

NB = neuroblastoma; P-value less than 0.05 considered significant.

Copyright: ©2019 Bui C. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Pediatr Dimensions, 2019 doi: 10.15761/PD.1000195 Volume 4: 2-2